News

June 30, 2020June 30, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

News, syndicated

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for ... Read more

June 30, 2020June 30, 2020

Ipatasertib Combo Fares Well in Early Results of IPATential150 Phase 3 Study

News

Adding ipatasertib to standard treatment for metastatic castration-resistant prostate cancer (mCRPC) significantly extended survival without disease worsening in a group of men whose tumors lack the PTEN protein, a Phase ... Read more

June 25, 2020June 25, 2020

Relugolix Granted FDA Priority Review as New Treatment Type

News

The U.S. Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) Myovant Sciences submitted earlier this year requesting the approval of relugolix for ... Read more

June 23, 2020June 23, 2020

Recommendation Against PSA Routine Screening May Have Contributed to Higher Rates of Advanced PC

News

The U.S. rates of advanced prostate cancer continued to rise in men 50 and older after the U.S. Preventive Services Task Force (USPSTF) recommended in 2012 against prostate-specific antigen ... Read more

June 19, 2020June 19, 2020

Veyonda Aids Radiation Therapy in Reaching Distant Lesions in Late-stage Cancer Trial

News

Veyonda (idronoxil) given in combination with low-dose radiation therapy was able to shrink metastatic lesions well outside the radiation field in about 27% of men with late-stage metastatic castration-resistant prostate cancer (mCRPC) in the DARRT-1 ... Read more

June 16, 2020June 16, 2020

Cancer DNA Levels in Blood Can Predict Treatment Responses

News

Analyses of circulating tumor DNA (ctDNA) — DNA from cancer cells circulating in the bloodstream — in blood samples can be used to predict which men with advanced prostate ... Read more

June 11, 2020June 11, 2020

Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds

News

Adding Xtandi (enzalutamide) to standard androgen deprivation therapy (ADT) significantly prolonged life by nearly a year for men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), final data from a ... Read more

June 9, 2020June 9, 2020

U.K. Study to Examine Genetic Screening for Large Prostate Cancer Population

News

Genetic screenings of the general population for prostate cancer are feasible, safe, and may be effective at identifying the disease in apparently healthy men who might otherwise remain undiagnosed, ... Read more

June 4, 2020June 4, 2020

NHS England Offers Xtandi, Zytiga to New PC Patients During COVID-19 Pandemic

News

Urged by Prostate Cancer UK, NHS England is making Xtandi (enzalutamide) and Zytiga (abiraterone acetate) available during the COVID-19 pandemic for men with newly diagnosed advanced prostate cancer. Access ... Read more

June 2, 2020June 2, 2020

ADT May Protect Prostate Cancer Patients from COVID-19, Study Suggests

News

Androgen deprivation therapy (ADT), a form of hormone therapy commonly used to treat prostate cancer, appears to confer protection against the virus that causes COVID-19, lowering the rate of ... Read more

Pin It on Pinterest